Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Aug 31, 2022 2:49pm
105 Views
Post# 34933232

RE:RE:Gene Therapies

RE:RE:Gene Therapies
Lol, yup, it's just capitalism, pof, survival of the fittest. 
 
That's swell if you're the survivor, pof. I don't think that enzyme replacement therapies will be a big deal, maybe not extinct but at least on the threatened list.
 
Why do you suppose that ArmaGen was able to enter a deal for Hunter syndrome with Shire for $15 million up front and $225 million in milestones back in 2014? You know, when Bioasis was making big talk and I was screaming for clinical programs to move this forward?
 
Now, $3 million up front and milestones of $138 million for four LSDs. Why do you suppose the value of LSDs dropped so drastically?

I'll stick with my thoughts about this.
 
jd
<< Previous
Bullboard Posts
Next >>